Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1996-7-8
|
| pubmed:abstractText |
A total of 76 patients with transitional cell carcinoma of the bladder were prospectively monitored with simultaneous serum value estimations of tumor polypeptide antigen (TPA), tumor-associated trypsin inhibitor (TATI), carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (beta-HCG), prostatic specific antigen (PSA), squamous cell carcinoma antigen (SCC), and CA 19-9 in different stages and phases of their disease. In locally advanced disease positive values were noted for TATI in 22/28 patients (78.5%), for TPA in 17/28 (60.7%), for CA 19-9 in 10/28 (35.7%), for CEA 11/28 (39.2%), for beta-HCG in 3/28 (10.7%), for PSA in 6/28 (21.4%), for SCC in 6/28 (21.4%), and for AFP in 0/28. In metastatic disease elevated levels were observed for TATI in 43/48 patients (89.5%), for TPA in 41/48 (85.4%), for CA 19-9 in 19/48 (39.5%), for CEA in 20/48 (41.6%), for beta-HCG in 6/48 (12.5%), for PSA in 7/48 (14.5%), for SCC in 8/48 (16.6%), and for AFP in 1/48 (2.1%). In metastatic disease TATI and TPA values were significantly modified in patients with complete remission and TATI, TPA, and CA 19-9 in patients with partial remission and nonresponders. In T2-T4-N0M0 tumors, TPA, TATI, CA 19-9, and CEA were significantly increased in nonresponders. In patients with complete remission, a change in serum TATI, TPA, and CA 19-9 levels cannot be evidenced with the available numbers. The concurrent determination of TATI and TPA in T2-T4N0M0 tumors and TATI, TPA, and CA 19-9 in generalized disease could predict the response to chemotherapy. This study indicates that only the determination of TATI and TPA and in some degree the CA 19-9 is a potential tool for monitoring the efficacy of treatment.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/CA-19-9 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Carcinoembryonic Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Chorionic Gonadotropin, beta...,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Serpins,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Polypeptide Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Trypsin Inhibitor, Kazal Pancreatic,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/alpha-Fetoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/squamous cell carcinoma-related...
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0277-3732
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
19
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
271-7
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8638540-Adult,
pubmed-meshheading:8638540-Aged,
pubmed-meshheading:8638540-Antigens, Neoplasm,
pubmed-meshheading:8638540-CA-19-9 Antigen,
pubmed-meshheading:8638540-Carcinoembryonic Antigen,
pubmed-meshheading:8638540-Carcinoma, Transitional Cell,
pubmed-meshheading:8638540-Chorionic Gonadotropin, beta Subunit, Human,
pubmed-meshheading:8638540-Female,
pubmed-meshheading:8638540-Humans,
pubmed-meshheading:8638540-Male,
pubmed-meshheading:8638540-Middle Aged,
pubmed-meshheading:8638540-Peptides,
pubmed-meshheading:8638540-Prostate-Specific Antigen,
pubmed-meshheading:8638540-Serpins,
pubmed-meshheading:8638540-Tissue Polypeptide Antigen,
pubmed-meshheading:8638540-Trypsin Inhibitor, Kazal Pancreatic,
pubmed-meshheading:8638540-Tumor Markers, Biological,
pubmed-meshheading:8638540-Urinary Bladder Neoplasms,
pubmed-meshheading:8638540-alpha-Fetoproteins
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
|
| pubmed:affiliation |
Department of Medical Oncology, 1st Department of Medical Oncology, Metaxas Cancer Hospital, Piraeus, Greece.
|
| pubmed:publicationType |
Journal Article
|